- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | Citizens reiterates Market Outperform rating on Rapport Therapeutics stock | 2 | Investing.com | ||
| 07.01. | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline | 692 | GlobeNewswire (Europe) | U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter... ► Artikel lesen | |
| 07.01. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | Goldman Sachs bekräftigt Kaufempfehlung für Rapport Therapeutics nach Studienerfolg bei Epilepsie-Medikament | 11 | Investing.com Deutsch | ||
| 19.12.25 | Rapport Therapeutics stock holds Buy rating at Goldman Sachs on epilepsy drug efficacy | 3 | Investing.com | ||
| 09.12.25 | H.C. Wainwright raises Rapport Therapeutics stock price target to $40 on strong seizure drug data | 1 | Investing.com | ||
| 09.12.25 | Starke Studiendaten: H.C. Wainwright hebt Kursziel für Rapport Therapeutics auf 40 $ an | 10 | Investing.com Deutsch | ||
| RAPPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.12.25 | Rapport Therapeutics: Citizens bestätigt "Market Outperform"-Rating nach neuen Studiendaten | 3 | Investing.com Deutsch | ||
| 05.12.25 | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures | 1 | GlobeNewswire (USA) | ||
| 06.11.25 | Rapport Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.09.25 | Truist Securities initiates Rapport Therapeutics stock with Buy rating | 9 | Investing.com | ||
| 11.09.25 | Rapport Therapeutics, Inc.: Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | 1 | GlobeNewswire (USA) | ||
| 10.09.25 | Rapport Therapeutics prices $250M stock at $26 per share | 2 | Seeking Alpha | ||
| 10.09.25 | Rapport Therapeutics prices $250 million public offering at $26 per share | 2 | Investing.com | ||
| 10.09.25 | Rapport Therapeutics, Inc.: Rapport Announces Pricing of Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.09.25 | Rapport Therapeutics launches $250 million public stock offering | 16 | Investing.com | ||
| 08.09.25 | Rapport Therapeutics, Inc.: Rapport Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.09.25 | Rapport Therapeutics: Stifel hebt Kursziel nach Studienerfolg deutlich auf 56 $ an | 4 | Investing.com Deutsch | ||
| 08.09.25 | Stifel raises Rapport Therapeutics stock price target to $56 on positive trial data | 2 | Investing.com |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOCRYST PHARMACEUTICALS | 5,726 | -0,42 % | Astria Therapeutics, Inc.: Stockholders Vote to Approve Acquisition by BioCryst Pharmaceuticals, Inc. | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,798 | +4,29 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen | |
| IMMUNITYBIO | 6,202 | -0,67 % | ImmunityBio-Aktie: Jetzt noch mit der Kursrakete mitfliegen? | Die ImmunityBio-Aktie machte einen Raketenstart ins neue Jahr. Bis gestern schoss der Kurs des Biotech-Unternehmens von 2,00 auf 5,50 US$ hoch. Doch am Dienstagmorgen bricht der Biotech-Titel im europäischen... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,440 | -1,21 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| CAPRICOR | 20,500 | -0,24 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,600 | -1,94 % | Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC) | CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,440 | -2,63 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,410 | +6,77 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| DBV TECHNOLOGIES | 4,330 | +12,03 % | DBV Technologies S.A.: DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing | Châtillon, France, January 16, 2026
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 80,00 | +1,91 % | Palvella Therapeutics Inc.: Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved ... | Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,590 | -7,56 % | MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know | ||
| KALVISTA PHARMACEUTICALS | 14,300 | +1,42 % | Multicare, KalVista to expand oral HAE treatment in Latin America | ||
| CARTESIAN THERAPEUTICS | 6,150 | -0,81 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential... ► Artikel lesen | |
| QUANTUM-SI | 1,315 | +6,91 % | Quantum-Si Inc - 8-K, Current Report | ||
| PROTARA THERAPEUTICS | 5,200 | +2,97 % | Protara-Aktie im Aufwind: Neue Daten zu Blasenkrebs-Therapie auf ASCO-Symposium erwartet |
Das Unternehmen RAPPORT THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +1,520 (+5,76 %) liegt der Kurs bei 27,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPPORT THERAPEUTICS INC finden Sie auf Wallstreet Online.